课题基金 / 基金详情

Ultra-high field GluCEST MRI and MRS in youth at risk for psychosis

Ultra-high field GluCEST MRI and MRS in youth at risk for psychosis
超高场 GluCEST MRI 和 MRS 在有精神病风险的青少年中的应用
批准号:
10574595
负责人:
DAVID R ROALF
金额:
$73.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-05-10 至 2025-02-28

项目摘要

项目成果

DAVID R ROALF的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT: Psychosis commonly develops in adolescence or early adulthood. Malfunctioning neurotransmitter systems, such as glutamate, are implicated in the disease progression of psychosis. Changes in brain glutamate in psychosis likely have several sources, as such, many frontline antipsychotic medications indirectly target the glutamate system and alleviate clinical symptoms. Unfortunately, monitoring in vivo alterations of the glutamate system within the brain are spatially limited by traditional magnetic resonance techniques. But, recently a novel 7T MRI technique (GluCEST) has shown that brain glutamate levels are lower across the brain in youth on the psychosis spectrum and patients with schizophrenia as compared to typically developing youth. Here, we propose to extend this novel work to directly measure glutamate within the brain of patients at risk for developing psychosis. Thus, this proposal is motivated by the need to better understand associations of brain neurochemistry, structure and function in both normal development and during early psychosis. In this study, we seek to 1) compare measures of glutamatergic development across the cortex in a cohort of typically developing (TD) youth, those at-clinical high-risk for psychosis (CHR) and individuals with frank psychosis (PSY); 2) associate changes in brain glutamate with age- and diagnosis- related structural network changes in those at risk for developing psychosis; and 3) to establish comparison data of glutamate measures at 7T MRI (1HMRS vs. GluCEST). We will recruit and follow 35 TD, CHR and PSY over the 5-year funding period. Imaging data will be acquired at 7T and analyses will leverage recent advances in network science and machine learning. We believe this innovative approach can significantly advance our understanding of the etiology of glutamate hypofunction in psychosis and provide advances to precision medicine in psychiatry. Through the proposed multi-level analysis, this innovative research will provide a substantial advance in our understanding of the neurodevelopmental substrates of psychosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ultra-high field GluCEST MRI and MRS in youth at risk for psychosis
  • 批准号:
    10359175
  • 项目类别:
  • 资助金额:
    $74.87万
  • 财政年份:
    2020
  • 负责人:
    DAVID R ROALF
  • 依托单位:
Ultra-high field GluCEST MRI and MRS in youth at risk for psychosis
  • 批准号:
    10162387
  • 项目类别:
  • 资助金额:
    $75.9万
  • 财政年份:
    2020
  • 负责人:
    DAVID R ROALF
  • 依托单位:
Olfactory and facial markers of developmental risk for psychosis in 22q11 deletion syndrome
  • 批准号:
    10217017
  • 项目类别:
  • 资助金额:
    $69.58万
  • 财政年份:
    2019
  • 负责人:
    DAVID R ROALF
  • 依托单位:
Olfactory and facial markers of developmental risk for psychosis in 22q11 deletion syndrome
  • 批准号:
    10468678
  • 项目类别:
  • 资助金额:
    $68.68万
  • 财政年份:
    2019
  • 负责人:
    DAVID R ROALF
  • 依托单位:
海外基金